Improving treatments and survivorship for teens and young adults with Hodgkin lymphoma
Official title: Advancing novel therapeutics and translational science to close the survivorship gap in pediatric, adolescent and young adult (AYA) lymphoma
Funded at Emory University · NIH-11166307 · Data updated 2026-11-12
This effort will bring newer targeted and immune-based therapies to adolescents and young adults with Hodgkin lymphoma to try to improve survival and reduce long-term side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | August 9, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $178,909 |
| NIH project number | 5R50CA285492-02 |
| Project ID | NIH-11166307 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adolescents and young adults with newly diagnosed or relapsed/refractory Hodgkin lymphoma who meet eligibility for clinical trials of immunotherapy or CD30‑targeted treatments.
✕Less likely to help
People without Hodgkin lymphoma, those outside the pediatric/AYA age range, or those who are medically ineligible for trial participation likely would not benefit directly from this work.
What this research studies
If you join work stemming from this project, researchers plan to test antibody‑drug conjugates, immunotherapies, and CD30‑targeted cellular approaches in teens and young adults with Hodgkin lymphoma. They will design trials that use emerging tumor and host biology to tailor treatment intensity and follow response. The project links trial data with national epidemiologic and follow‑up data to better understand long‑term outcomes. At Emory and through national collaborations, the team will also work to improve clinical trial access and enrollment for AYA patients.
Why it matters
Potential benefit: Could offer safer, more effective treatment options and better long-term survival and quality of life for adolescents and young adults with Hodgkin lymphoma.
How similar studies have gone: Antibody‑drug conjugates and immune checkpoint therapies have shown benefit in Hodgkin lymphoma in adults, but applying and tailoring these approaches for children and AYAs is still relatively new.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Castellino, Sharon Marie — Emory University
- Study coordinator: Castellino, Sharon Marie
Related research
Other NIH-funded projects on the same topics.
-
Resilience-based program to boost quality of life after lymphoma treatment
A virtual group program called SMART3RP-lymphoma will be offered to lymphoma survivors 0–2 years after finishing treatment to help improve their long-term quality of life.
-
Advancing new therapies to close the survivorship gap for pediatric and young adult lymphoma
A cancer research grant aims to speed up safer, targeted treatments for Hodgkin lymphoma in kids and young adults to improve survival and long-term health.
-
Improving treatments for young people with Hodgkin Lymphoma
This study is looking for better ways to treat young people with Hodgkin Lymphoma by trying out new therapies and making it easier for them to join clinical trials, all with the hope of helping them live longer and feel better during treatment.
-
Understanding how survivorship care plans affect health outcomes for cancer survivors
A study will look at whether survivorship care plans help reduce deaths and improve health for adults who have survived cancer.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Preventing follicular lymphoma progression with precision therapy
This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.